Q4 2025
Released Mar 3, 2026, before the open
10-K filed Mar 3, 2026, 62 days after period end · 0001628280-26-013569
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$838.00K$838.00K derived−61.6% vs Q4 2024−31.6% vs Q3 2025
Net Income-$46.08M-$46.08M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$48,608,000N/M
Operating Cash Flowderived-$37,256,000N/M
Free Cash Flowderived-$37,546,000N/M
Margins · derived
Operating margin-5800.5%−3774.7 pt vs Q4 2024
Net margin-5498.7%−3562.1 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $838.00K | $2.18M | $0.00 | — |
| Net Income | -$46.08M | -$42.28M | -$65.64M | -$39.28M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR